5 recruiting, 4 completed, 2 active not recruiting, 1 enrolling by invitation. 14 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Recruiting 5, Completed 4, Active not recruiting 2, Enrolling by invitation 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Enrolling by invitation 1 |
| Phase 3 | 1 | Completed 1 |
Follow Common Variable Immunodeficiency: new trials by email Literature Review of Common Variable Immunodeficiency trials Research Report on Common Variable Immunodeficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD) Hematopoietic stem cell transplant (HSCT) - Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder | Phase 2 | Recruiting | Paul Szabolcs | 25 | 2026-05-04 | 2026-05-15 |
| Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia IgPro20 - Multiple Myeloma, Hypogammaglobulinemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 100 | 2025-05-08 | 2026-10-05 |
| Leniolisib for Immune Dysregulation in CVID Leniolisib - Common Variable Immunodeficiency (CVID) | Phase 2 | Completed | Pharming Technologies B.V. | 27 | 2025-02-12 | 2026-09-18 |
| Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency Fisetin, Placebo - Common Variable Immunodeficiency, Interstitial Lung Disease Due to Systemic Disease | Phase 2 | Active not recruiting | Avni Joshi | 20 | 2023-04-12 | 2026-06-30 |
| Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease Abatacept, Placebo - Interstitial Lung Disease, Common Variable Immunodeficiency | Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 38 | 2021-07-14 | 2026-07-22 |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Busulfan test dose, Fludarabine, Busulfan - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2020-09-22 | 2026-10-19 |
| Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2018-09-04 | 2026-03-17 |
| Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Thiotepa--single daily dose, Thiotepa--escalated dose - Bone Marrow Failure Syndrome, Thalassemia | Phase 1 / Phase 2 | Completed | University of Florida | 6 | 2018-06-15 | 2023-09-15 |
| Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency Rituximab (RTX) and Azathioprine (AZA), Placebos - Granulomatous and Lymphocytic Interstitial Lung Disease | Phase 2 | Withdrawn | Medical College of Wisconsin | 2016-05-02 | 2020-03-10 | |
| Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies Immunosuppression Only Conditioning -Closed with amendment L, Reduced Intensity Conditioning, Myeloablative Conditioning-Closed with amendment L - Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency | Phase 2 | Recruiting | National Cancer Institute (NCI) | 354 | 2015-11-19 | 2026-10-26 |
| Study of Efficacy of CDZ173 in Patients With APDS/PASLI CDZ173, Placebo - Common Variable Immunodeficiency (CVID), APDS / PASLI | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 37 | 2015-08-24 | 2022-08-10 |
| Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases CD3/CD19 negative allogeneic hematopoietic stem cells - Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified | Phase 1 / Phase 2 | Enrolling by invitation | Paul Szabolcs | 16 | 2013-06-20 | 2025-12-15 |
| Immune Disorder HSCT Protocol Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan - Immune Deficiency Disorders, Severe Combined Immunodeficiency | Phase 2 | Completed | Washington University School of Medicine | 28 | 2013-04-29 | 2026-10-27 |
| "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency PPS, PnCJ PPS - Common Variable Immunodeficiency | Phase 2 | Terminated | Institut National de la Santé Et de la Recherche Médicale, France | 45 | 2009-06-01 | 2016-02-24 |
Lymphoproliferative Disorders (5) · Granulomatous Disease, Chronic (4) · Immune System Diseases (4) · Severe Combined Immunodeficiency (4) · Autoimmune Diseases (3) · Opportunistic Infections (3) · T cell immunodeficiency primary (3) · Wiskott-Aldrich Syndrome (3) · DiGeorge Syndrome (2) · Hyper-IgM Immunodeficiency Syndrome (2) · Lymphohistiocytosis, Hemophagocytic (2) · Activated PI3K-delta Syndrome (1) · Adrenoleukodystrophy (1) · Agammaglobulinemia (1)
Immunologic Deficiency Syndromes (13) · Immune System Diseases (10) · Hemic and Lymphatic Diseases (8) · Lymphatic Diseases (7) · Immunoproliferative Disorders (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Hematologic Diseases (5) · Chronic Disease (4) · DNA Repair-Deficiency Disorders (4) · Disease Attributes (4) · Genetic Diseases, X-Linked (4) · Hemorrhagic Disorders (4) · Infant, Newborn, Diseases (4) · Leukocyte Disorders (4)
Busulfan (2) · Cyclophosphamide (2) · Mycophenolic Acid (2) · Tacrolimus (2) · fludarabine (2) · leniolisib (2) · Abatacept (1) · Absorptiometry, Photon (1) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Azathioprine (1) · Biopsy (1) · Electrocardiography (1) · Hizentra (1) · Melphalan (1)
National Cancer Institute (NCI) (3) · Paul Szabolcs (2) · Avni Joshi (1) · Children's Hospital Medical Center, Cincinnati (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Medical College of Wisconsin (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · Pharming Technologies B.V. (1) · University of Florida (1) · Washington University School of Medicine (1)
United States (12) · United Kingdom (2) · Belarus (1) · Czechia (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · Netherlands (1) · Russia (1) · Spain (1)
Dimana Dimitrova, M.D. (2) · Paul Szabolcs, MD (2) · Avni Joshi, MD, MS (1) · Biljana Horn, MD (1) · John M Routes, MD (1) · Koneti V Rao, MD (1) · Michael Jordan (1) · Sung-Yun Pai, M.D. (1) · Virgil Dalm, MD (1) · Zainab Shahid, MBBS (1)
PMID 28972011, PMID 30713498, PMID 31599480, PMID 36399712, PMID 41091701, PMID 41370196
2014 (1)